Demographic and baseline ocular characteristics of patients included in this post hoc analysis
| Brolucizumab 6 mg (n=700) | Aflibercept 2 mg (n=696) | |
| Age, mean (SD), years | 75.7 (8.8) | 75.7 (8.3) |
| Females, n (%) | 393 (56.1) | 387 (55.6) |
| Ethnicity, n (%) | ||
| White | 597 (85.3) | 595 (85.5) |
| Asian | 81 (11.6) | 76 (10.9) |
| BCVA, mean (SD), letters | 61.2 (13.1) | 60.4 (13.3) |
| CST, mean (SD), μm | 468.2 (168.6) | 461.8 (149.4) |
| Type of CNV, n (%) | ||
| Predominantly classic | 252 (36.0) | 249 (36.0) |
| Minimally classic | 71 (10.1) | 67 (9.7) |
| Occult | 377 (53.9) | 375 (54.3) |
| Lesion area associated with CNV, mean (SD), mm2 | 3.6 (3.6) | 3.7 (3.9) |
| Presence of fluid, n (%) | ||
| SRF | 485 (69.3) | 492 (70.7) |
| IRF | 329 (47.0) | 316 (45.4) |
| Sub-RPE fluid | 282 (40.3) | 274 (39.4) |
BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CST, central subfield thickness; IRF, intraretinal fluid; RPE, retinal pigment epithelium; SRF, subretinal fluid.